Immutep Ltd has released a press release.
First Data From Phase IIb Clinical Trial of Imp321
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Prima BioMed Files U.S Shelf Registration Statement
- PRR Enters Agreement with Sydys to Advance CVac Program
- Japanese Patent Grants For IMP321 In Cancer
- Appendix 4C - quarterly March 2016
- Proposed Acquisition of Immutep
Later from Immutep
- PRR Collaborates In New Clinical Trial For Imp321
- European Patent Grants for IMP731 Antibody
- Appendix 4E & 2016 Full Year Statutory Accounts
- S&P DJ Indices Announces March Quarterly Rebalance
- S&P DJ Indices Announces March Quarterly Review
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep